TransCode discovered that metastatic tumor cells cannot survive without the expression of a specific non-coding RNA molecule, miR-10b, which regulates the viability of metastatic tumor cells. Against this framework, TransCode has designed the first known cancer therapeutic, TTX-MC138, that efficiently inhibits miR-10b in metastatic tumor cells, resulting in the complete regression of established metastases with no recurrence and no toxicity.